Evidence map›Paper›PMID 32509875›Full record

ArticleBioMed research international2020

Lutein plus Water Chestnut (

Hidetoshi Ishida, Teppei Shibata, Shinsuke Shibata, Yuki Tanaka, Hiroshi Sasaki, Eri Kubo

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Inhibitory effects of water chestnut (Journal of diabetes and metabolic disorders · 2026
    Article
  2. Different Varieties of Water Caltrop (Foods (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hidetoshi IshidaDepartment of Ophthalmology, Kanazawa Medical University, Ishikawa 9200293, Japan.
Teppei ShibataDepartment of Ophthalmology, Kanazawa Medical University, Ishikawa 9200293, Japan.
Shinsuke ShibataDepartment of Ophthalmology, Kanazawa Medical University, Ishikawa 9200293, Japan.
Yuki TanakaSupplement Development & Promotion Group, Santen Pharmaceutical Co., Ltd., Tokyo 1030022, Japan.
Hiroshi SasakiDepartment of Ophthalmology, Kanazawa Medical University, Ishikawa 9200293, Japan.ORCID https://orcid.org/0000-0002-6458-5330
Eri KuboDepartment of Ophthalmology, Kanazawa Medical University, Ishikawa 9200293, Japan.ORCID https://orcid.org/0000-0001-6789-9311
Kanazawa Medical University · JPSanten (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related cataract (ARC) is the major cause of blindness worldwide. The most significant factors are the maximal exposure of the eye lens to environmental stressors, including oxidative and glycative load. The administration of antioxidant and antiglycative supplements may reduce the risk of cataract progression. In this study, the effects of lutein (LU) and water chestnut (

Indexed as

Lens, CrystallineAnimalsAntioxidantsCataractCells, CulturedEpithelial CellsLuteinLythraceaePlant ExtractsRatsAntioxidantsLuteinPlant Extracts

Identifiers

PMID32509875
PMCPMC7254081
OpenAlexW3024736841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.